Is intravenous iron indicated in a patient with serum iron of 52 µg/dL, transferrin saturation of 20 %, and ferritin of 110 ng/mL despite daily oral iron therapy?

IV Iron Is NOT Indicated Based on These Values Alone

With a ferritin of 110 ng/mL and transferrin saturation of 20%, IV iron is generally not indicated unless there is functional iron deficiency despite adequate iron stores, ongoing blood losses that cannot be replaced with oral iron, or specific conditions like heart failure, chronic kidney disease on dialysis, or inflammatory bowel disease with active inflammation.

Clinical Context Determines the Decision

The key issue here is that your patient has borderline adequate iron parameters (ferritin 110 ng/mL, TSAT 20%) but is failing oral iron therapy. This creates a clinical dilemma that requires understanding the underlying condition.

For Chronic Kidney Disease (Most Relevant Given the Evidence)

If this patient has CKD on hemodialysis:

• Yes, IV iron is indicated 1
• The NKF-K/DOQI guidelines explicitly state that oral iron fails to maintain adequate stores in most hemodialysis patients receiving erythropoietin 1
• Target parameters are TSAT ≥20% AND ferritin ≥100 ng/mL 1
• Your patient is at the threshold, and failure of oral iron is an indication to switch to IV iron 1
• Recommended approach: Give 1.0 g IV iron over 8-10 weeks and observe response 1

If this patient has CKD not on dialysis:

• The decision is more nuanced
• A trial of IV iron (1.0 g over 8-10 weeks) is reasonable if hemoglobin remains <11 g/dL despite oral iron 1
• Oral iron may still work in some non-dialysis CKD patients 1

For Heart Failure

If this patient has heart failure with reduced ejection fraction:

• Yes, IV iron is indicated 2
• The 2022 AHA/ACC/HFSA guidelines define iron deficiency as ferritin <100 ng/mL OR ferritin 100-300 ng/mL with TSAT <20% 2
• Your patient meets criteria (ferritin 110 with TSAT 20%)
• However, recent meta-analysis data suggests the benefit may be restricted to patients with TSAT <20% 3
• Since your patient has TSAT exactly at 20%, the benefit is uncertain
• Oral iron does not work in heart failure - the IRONOUT HF trial showed no benefit 2

For Inflammatory Bowel Disease

If this patient has active IBD:

• Yes, IV iron is indicated 4
• Active inflammation compromises oral iron absorption 4
• IV iron should be used with active inflammation and compromised absorption 4

For General Iron Deficiency Without These Conditions

If this is simple iron deficiency anemia:

• No, IV iron is not yet indicated 4, 5
• The AGA guidelines state IV iron should be used if: (1) oral iron not tolerated, (2) ferritin doesn't improve with oral iron trial, or (3) condition where oral iron unlikely to be absorbed 4
• Your patient has had a trial of oral iron that failed
• This meets criteria for IV iron 4

The Critical Question: Why Did Oral Iron Fail?

The failure of oral iron despite adequate dosing suggests one of three scenarios:

1. Ongoing blood losses exceed absorption - common in hemodialysis, GI bleeding, heavy menstrual bleeding
2. Malabsorption - inflammatory states, celiac disease, bariatric surgery, autoimmune gastritis
3. Functional iron deficiency - iron stores adequate but cannot be mobilized fast enough for erythropoiesis demands

Practical Algorithm

Step 1: Identify the underlying condition

• CKD on dialysis → Give IV iron 1
• Heart failure with TSAT <20% → Give IV iron 2, 3
• Active IBD → Give IV iron 4
• Ongoing blood losses (GI bleeding, menorrhagia) → Give IV iron 4, 5

Step 2: If none of the above, assess for malabsorption

• Post-bariatric surgery → Give IV iron 4
• Celiac disease, autoimmune gastritis → Give IV iron 4

Step 3: If simple IDA with failed oral trial

• Give IV iron - failure to respond to adequate oral iron trial is an indication 4

Dosing Recommendations

If you proceed with IV iron:

• Preferred: High-dose formulations requiring 1-2 infusions (ferric carboxymaltose, iron isomaltoside, ferric derisomaltose) 4, 5
• Dose: Calculate total iron deficit or give 1000 mg over 8-10 weeks 1
• Monitoring: Recheck CBC and iron parameters 4-8 weeks after last infusion 5
• Target: Hemoglobin increase of 1-2 g/dL within 4-8 weeks 5

Important Caveats

• Do not give IV iron if active infection present - 90% of clinicians withhold in this setting 6
• Ferritin is an acute phase reactant - may be falsely elevated with inflammation 1
• TSAT <20% has high sensitivity for iron deficiency even when ferritin is elevated 5, 3
• Hypophosphatemia risk - occurs in ~28% with ferric carboxymaltose; consider iron isomaltoside instead 7
• Don't recheck iron parameters within 4 weeks of IV iron administration - results will be spuriously elevated 5